[
  {
    "ts": "2025-06-18T19:39:00+00:00",
    "headline": "Incyte Announces FDA Approval of Monjuvi速 (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma",
    "summary": "WILMINGTON, Del., June 18, 2025--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi速 (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).",
    "url": "https://finance.yahoo.com/news/incyte-announces-fda-approval-monjuvi-193900081.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "4ec7e8ba-70cc-3d13-ba57-628a5b275488",
      "content": {
        "id": "4ec7e8ba-70cc-3d13-ba57-628a5b275488",
        "contentType": "STORY",
        "title": "Incyte Announces FDA Approval of Monjuvi速 (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma",
        "description": "",
        "summary": "WILMINGTON, Del., June 18, 2025--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi速 (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).",
        "pubDate": "2025-06-18T19:39:00Z",
        "displayTime": "2025-06-18T19:39:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/ecdb5c06622ad037dd2f434363add477",
          "originalWidth": 480,
          "originalHeight": 229,
          "caption": "MONJUVI logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jlSgHN9C81BAZs4.s1iTDQ--~B/aD0yMjk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ecdb5c06622ad037dd2f434363add477.cf.webp",
              "width": 480,
              "height": 229,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3t3_YcFKtSCzrv0UT6Pxxg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ecdb5c06622ad037dd2f434363add477.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incyte-announces-fda-approval-monjuvi-193900081.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incyte-announces-fda-approval-monjuvi-193900081.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]